Lanfear Dennis M 4

What Happened
Dennis M. Lanfear, President, CEO and a director of Coherus Oncology (CHRS), received two awards on January 23, 2026: 375,000 restricted stock units (RSUs) and a derivative award covering 750,000 shares (a stock option-type award). Both grants are reported at $0.00 cash paid (standard for equity compensation grants). These are compensation awards, not open-market purchases or sales.

Key Details

• Transaction date: January 23, 2026; Form 4 filed January 26, 2026 (appears timely).
• Grants reported: 375,000 RSUs (reported as Award/Acquisition) and 750,000-share derivative award (option-type) at $0.00.
• RSU vesting (F1): 50% vest May 20, 2027; remaining 50% vest March 20, 2029, subject to continued service.
• Option vesting (F4): 1/4 of option vests on the one-year anniversary of Jan 23, 2026, then 1/48th monthly thereafter, subject to continued service. The derivative entry reflects the option-like award (not an immediate exercise).
• The filing notes additional holdings are held via the Lanfear Revocable Trust and Lanfear Capital Advisors, LLC (F2, F3). The filing excerpt provided does not state total post-transaction share ownership.
• No indication of sale, exercise-for-cash, gift, or 10b5-1 plan in this filing.

Context
These awards are compensation grants that vest over time and do not represent shares immediately sold or purchased in the market. RSUs convert to common stock upon vesting; the option-like award becomes exercisable according to the stated vesting schedule. Such grants are common for executive compensation and should be viewed as part of the CEO’s pay package rather than an immediate market transaction.